214 related articles for article (PubMed ID: 27431011)
41. Induction of factor VIII-specific unresponsiveness by intrathymic factor VIII injection in murine hemophilia A.
Madoiwa S; Yamauchi T; Kobayashi E; Hakamata Y; Dokai M; Makino N; Kashiwakura Y; Ishiwata A; Ohmori T; Mimuro J; Sakata Y
J Thromb Haemost; 2009 May; 7(5):811-24. PubMed ID: 19220731
[TBL] [Abstract][Full Text] [Related]
42. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.
Mariani G; Kroner B;
Haematologica; 2001 Nov; 86(11):1186-93. PubMed ID: 11694405
[TBL] [Abstract][Full Text] [Related]
43. Progress toward inducing immunologic tolerance to factor VIII.
Scott DW; Pratt KP; Miao CH
Blood; 2013 May; 121(22):4449-56. PubMed ID: 23502223
[TBL] [Abstract][Full Text] [Related]
44. Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity.
Doering CB; Gangadharan B; Dukart HZ; Spencer HT
Mol Ther; 2007 Jun; 15(6):1093-9. PubMed ID: 17387335
[TBL] [Abstract][Full Text] [Related]
45. Expression and characterization of recombinant murine factor VIII.
Doering C; Parker ET; Healey JF; Craddock HN; Barrow RT; Lollar P
Thromb Haemost; 2002 Sep; 88(3):450-8. PubMed ID: 12353075
[TBL] [Abstract][Full Text] [Related]
46. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A.
Evans GL; Morgan RA
Proc Natl Acad Sci U S A; 1998 May; 95(10):5734-9. PubMed ID: 9576953
[TBL] [Abstract][Full Text] [Related]
47. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype.
Jarvis MA; Levin LG; Harrison JA; DePianto DJ; Suzuki CM; Ziaja CL; Brown JE; Jolly KW; Reisner HM; Abildgaard CF; Powell JS
Thromb Haemost; 1996 Feb; 75(2):318-25. PubMed ID: 8815584
[TBL] [Abstract][Full Text] [Related]
48. Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice.
Wroblewska A; van Haren SD; Herczenik E; Kaijen P; Ruminska A; Jin SY; Zheng XL; van den Biggelaar M; ten Brinke A; Meijer AB; Voorberg J
Blood; 2012 May; 119(22):5294-300. PubMed ID: 22498747
[TBL] [Abstract][Full Text] [Related]
49. Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low-dose regimens.
Lin PC; Liao YM; Tsai SP; Chang TT
Pediatr Blood Cancer; 2011 Dec; 57(6):1029-33. PubMed ID: 21793191
[TBL] [Abstract][Full Text] [Related]
50. von Willebrand factor and transforming growth factor-beta modulate immune response against coagulation factor VIII in FVIII-deficient mice.
Kallas A; Kuuse S; Maimets T; Pooga M
Thromb Res; 2007; 120(6):911-9. PubMed ID: 17376515
[TBL] [Abstract][Full Text] [Related]
51. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients.
Reding MT; Lei S; Lei H; Green D; Gill J; Conti-Fine BM
Thromb Haemost; 2002 Oct; 88(4):568-75. PubMed ID: 12362225
[TBL] [Abstract][Full Text] [Related]
52. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
53. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
Lusher JM
Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
[TBL] [Abstract][Full Text] [Related]
54. Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate.
Oldenburg J; Jiménez-Yuste V; Peiró-Jordán R; Aledort LM; Santagostino E
Haemophilia; 2014 Jan; 20(1):83-91. PubMed ID: 24354480
[TBL] [Abstract][Full Text] [Related]
55. Management of factor VIII inhibitors.
Dimichele DM
Int J Hematol; 2006 Feb; 83(2):119-25. PubMed ID: 16513529
[TBL] [Abstract][Full Text] [Related]
56. Rapid acquisition of immunologic tolerance to factor VIII and disappearance of anti-factor VIII IgG4 after prophylactic therapy in a hemophilia A patient with high-titer factor VIII inhibitor.
Moorehead PC; Thibeault L; Tuttle A; Grabell J; Dwyre L; Silva M; James P; Lillicrap D
J Pediatr Hematol Oncol; 2015 May; 37(4):e220-2. PubMed ID: 25411864
[TBL] [Abstract][Full Text] [Related]
57. Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice.
Krishnamoorthy S; Liu T; Drager D; Patarroyo-White S; Chhabra ES; Peters R; Josephson N; Lillicrap D; Blumberg RS; Pierce GF; Jiang H
Cell Immunol; 2016 Mar; 301():30-9. PubMed ID: 26775174
[TBL] [Abstract][Full Text] [Related]
58. A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells.
Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Chuah M; VandenDriessche T; Miao CH; Hough C; Lillicrap D
Blood; 2009 Jul; 114(3):677-85. PubMed ID: 19458355
[TBL] [Abstract][Full Text] [Related]
59. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.
DiMichele D; Kroner B;
Haematologica; 2000 Oct; 85(10 Suppl):40-2; discussion 42-4. PubMed ID: 11187869
[TBL] [Abstract][Full Text] [Related]
60. Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice.
Zhang AH; Skupsky J; Scott DW
Blood; 2011 Feb; 117(7):2223-6. PubMed ID: 21160036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
